Resverlogix Corp. (TSE:RVX – Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.05 and last traded at C$0.06, with a volume of 11000 shares traded. The stock had previously closed at C$0.06.
Resverlogix Stock Performance
The stock has a fifty day moving average price of C$0.06 and a 200-day moving average price of C$0.06. The firm has a market capitalization of C$16.33 million, a price-to-earnings ratio of -1.20 and a beta of 0.78.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than Resverlogix
- Consumer Staples Stocks, Explained
- 3 Technologies to Challenge NAND Flash Dominance in AI
- Manufacturing Stocks Investing
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- Insider Trading – What You Need to Know
- Packaging Corporation of America: Buy The Dip
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
